Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to -$353.4 million.

  • Ligand Pharmaceuticals' Cash from Investing Activities fell 65998.24% to -$353.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.8 million, marking a year-over-year decrease of 24497.38%. This contributed to the annual value of -$143.7 million for FY2024, which is 112978.94% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$353.4 million for Q3 2025, which was down 65998.24% from -$10.7 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Cash from Investing Activities peaked at $113.9 million during Q1 2022, and registered a low of -$353.4 million during Q3 2025.
  • For the 5-year period, Ligand Pharmaceuticals' Cash from Investing Activities averaged around -$16.9 million, with its median value being -$7.3 million (2022).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 82470.88% in 2024, then skyrocketed by 22964.24% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Cash from Investing Activities stood at -$35.7 million in 2021, then surged by 79.6% to -$7.3 million in 2022, then plummeted by 41.19% to -$10.3 million in 2023, then tumbled by 275.56% to -$38.6 million in 2024, then plummeted by 815.12% to -$353.4 million in 2025.
  • Its Cash from Investing Activities stands at -$353.4 million for Q3 2025, versus -$10.7 million for Q2 2025 and $4.9 million for Q1 2025.